Atlas Trials

A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer

Clinical trial NCT06584435 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06584435
Sponsor
Tianjin Medical University Second Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
High-risk Renal Cell Carcinoma
Start date
2022-10-10
Primary completion
2025-11-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.